Marla Persky - Jun 4, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Director
Signature
/s/ Beth Hecht, Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jun 4, 2025
Transactions value $
$0
Form type
4
Date filed
6/4/2025, 07:05 PM
Previous filing
Jun 5, 2024
Next filing
Sep 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
PERSKY MARLA Director C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht, Attorney-in-Fact 2025-06-04 0001270354

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +50K +46.51% $0.00 158K Jun 4, 2025 Direct F1
holding XERS Common Stock 6.37K Jun 4, 2025 By: Marla Susan Persky Revocable Trust u/a dated 9/23/2000 F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders.
F2 The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.